Aurinia settles patent dispute with Teva over generic voclosporin

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/24/2026

1. DECK
2. RNG
3. WDC
4. BYD
5. SPOT
6. WCN
7. BMY
8. FIX
9. TSCO
10. BE

Go back to Aurinia settles patent dispute with Teva over generic voclosporin

Aurinia Settles Patent Litigation with Teva

August 19, 2026 4:05 PM EDT

EDMONTON, Alberta--(BUSINESS WIRE)-- Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) today announced that it and its subsidiary, Aurinia Pharma U.S., Inc., (collectively, Aurinia) have entered into a settlement agreement with Teva Pharmaceuticals Inc. (Teva) to resolve patent infringement litigation relating to Tevas filing of an Abbreviated New Drug Application seeking to market its generic 7.9 mg voclosporin oral capsules in the United States.

Under the terms of the settlement, Teva has stipulated that Aurinias U.S. Patent Nos. 10,286,036 and 11,622,991 (which expire in December 2037) are enforceable, valid, and would be infringed by commercial sales... More